- Home
- DSL vs PCRX Comparison
DSL vs PCRX Comparison
Compare DSL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- PCRX
- Stock Information
- Founded
- DSL 2013
- PCRX 2006
- Country
- DSL United States
- PCRX United States
- Employees
- DSL N/A
- PCRX N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- PCRX Health Care
- Exchange
- DSL Nasdaq
- PCRX Nasdaq
- Market Cap
- DSL 1.4B
- PCRX 1.2B
- IPO Year
- DSL N/A
- PCRX 2011
- Fundamental
- Price
- DSL $12.47
- PCRX $26.67
- Analyst Decision
- DSL
- PCRX Buy
- Analyst Count
- DSL 0
- PCRX 6
- Target Price
- DSL N/A
- PCRX $30.00
- AVG Volume (30 Days)
- DSL 343.2K
- PCRX 766.6K
- Earning Date
- DSL 01-01-0001
- PCRX 08-05-2025
- Dividend Yield
- DSL 10.59%
- PCRX N/A
- EPS Growth
- DSL N/A
- PCRX N/A
- EPS
- DSL N/A
- PCRX N/A
- Revenue
- DSL N/A
- PCRX $705,848,000.00
- Revenue This Year
- DSL N/A
- PCRX $7.36
- Revenue Next Year
- DSL N/A
- PCRX $10.07
- P/E Ratio
- DSL N/A
- PCRX N/A
- Revenue Growth
- DSL N/A
- PCRX 2.25
- 52 Week Low
- DSL $10.58
- PCRX $12.61
- 52 Week High
- DSL $13.24
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- DSL 70.83
- PCRX 67.86
- Support Level
- DSL $12.18
- PCRX $25.14
- Resistance Level
- DSL $12.29
- PCRX $27.04
- Average True Range (ATR)
- DSL 0.06
- PCRX 0.78
- MACD
- DSL 0.02
- PCRX 0.18
- Stochastic Oscillator
- DSL 93.55
- PCRX 88.79
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.